Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Zvi Laron; Haim Werner

doi:10.1016/j.ghir.2023.101548

Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Growth Horm IGF Res. 2023 Aug:71:101548. doi: 10.1016/j.ghir.2023.101548. Epub 2023 Jul 22.

Authors

Zvi Laron¹, Haim Werner²

Affiliations

¹ Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva, Israel. Electronic address: Laronz@clalit.org.il.
² Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel.

PMID: 37598644
DOI: 10.1016/j.ghir.2023.101548

Abstract

Insulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.

Keywords: Atherosclerotic cardiovascular disease; IGF-I; IGF-treatment; Lipoprotein(a).

Publication types

Review

MeSH terms

Atherosclerosis*
Cardiovascular Diseases* / prevention & control
Child
Growth Hormone
Human Growth Hormone*
Humans
Insulin-Like Growth Factor I* / therapeutic use
Lipoprotein(a)

Substances

Growth Hormone
Human Growth Hormone
Insulin-Like Growth Factor I
Lipoprotein(a)